Clinical Trial Update: Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass [Phase 2]

View source ↗

Summary

This Phase 2 trial update evaluates pretreatment with levosimendan to facilitate weaning from cardiopulmonary bypass in patients with coronary heart disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Heart Disease

Drugs mentioned

• Levosimendan (levosimendan)

Snippet

Sponsor: Orion Corporation, Orion Pharma | Conditions: Coronary Heart Disease | Phase 2 | Status: COMPLETED